Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis - Summary - MDSpire

Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis

  • By

  • Feng Li

  • Jian Zhang

  • Xiangbo An

  • Jianfei Liu

  • Benkei Li

  • Haiwei Li

  • Li Jun

  • Ningfang Wang

  • Guinan Jiang

  • Ye Jiang

  • Dehui Zhang

  • Fei Gao

  • Lei Song

  • Jun Zhou

  • Wenheng Zheng

  • Min Ji

  • Feng Wang

  • June 1, 2026

  • 0 min

Share

Objective:

To assess the efficacy and safety of balloon-occluded HAIC (bHAIC) based on the FOLFOX regimen in unresectable HCC.

Key Findings:
  • Best ORR for 45 evaluable patients was 53.3% (RECIST 1.1) and 82.2% (mRECIST).
  • 88.9% ORR was observed in 36 treatment-naive patients according to mRECIST, with 15 achieving complete response.
  • 77.3% of patients with elevated AFP levels had a reduction of over 50% in their AFP levels.
  • All adverse events were manageable through medication or dose modifications.
Interpretation:

Remove this section.

Limitations:
  • Single-arm design may limit generalizability.
  • Interim analysis may not capture long-term outcomes.
Conclusion:

Remove this section.

Original Source(s)

Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis

  • by Feng Li, Jian Zhang, Xiangbo An, Jianfei Liu, Benkei Li, Haiwei Li, Li Jun, Ningfang Wang, Guinan Jiang, Ye Jiang, Dehui Zhang, Fei Gao, Lei Song, Jun Zhou, Wenheng Zheng, Min Ji, Feng Wang

  • June 1, 2026

Related Content

Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome

Target receptor expression dictates the selective intra-tumoral targeting of CD8+ T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients

Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study